GlassScriptPhysician profile
Tara C Buck
NPI 1811074529
$10,070.62
in general payments reported to CMS, 2019-2025
27 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,941 · 2022: $1,193 · 2023: $2,734 · 2024: $3,731 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,861 · Education: $74.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,861.20 |
| Education | $74.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,710.14 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,928.34 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,450.56 | 2021-2025 | |
| Glaxosmithkline, LLC. | $483.75 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $392.20 | 2021-2024 | Xarelto |
| Pfizer INC. | $387.20 | 2022-2025 | |
| Lilly USA, LLC | $350.38 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $245.57 | 2023-2024 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $219.96 | 2021-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $203.01 | 2023-2024 | Rexulti, Nuedexta |
| Amgen INC. | $199.03 | 2021-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.71 | 2021-2025 | Jardiance, Synjardy |
| Atricure, INC. | $196.93 | 2023 | |
| Abbott Laboratories | $183.33 | 2022-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $143.75 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $133.24 | 2023-2024 | Auvelity |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Exact Sciences Corporation | $121.83 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $121.82 | 2022-2024 | |
| Lundbeck LLC | $70.40 | 2024 | Rexulti |
| Corcept Therapeutics | $50.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.53 | 2023 | Xifaxan |
| Boston Scientific Corporation | $34.16 | 2023 | |
| Idorsia Pharmaceuticals US INC | $26.13 | 2023-2024 | Quviviq |
| Philips North America LLC | $19.93 | 2024 | (Ck7) Extended Holter |
| Kowa Pharmaceuticals America, INC. | $16.84 | 2021 | |
| Currax Pharmaceuticals LLC | $15.88 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.